<DOC>
	<DOCNO>NCT01037192</DOCNO>
	<brief_summary>Our hypothesis large-dose , extended-interval vancomycin ( 30 mg/kg IV q24h ) administration provide non-inferior clinical efficacy microbiological efficacy standard vancomycin ( 15 mg/kg IV q12h ) administration skin soft tissue infection outpatient setting .</brief_summary>
	<brief_title>Evaluating Use Large-dose , Extended Interval Vancomycin Intravenous Administration Skin Soft Tissue Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Age 19 70 year Weight 40 80 kg Suspected confirm skin soft tissue infection vancomycin indicate Subject refer admitted OPAT Infectious Disease Specialist Emergency Physician Subject able provide inform consent Known history allergy vancomycin Pregnancy Granulocytopenia ( &lt; 1x109/L ) Renal impairment ( serum creatinine &gt; 177 Âµmol/L eGFR &lt; 50 mL/min ) Known history vestibular disease hearing loss Subjects treat vancomycin within previous month Subjects receive 24 hour vancomycin Subjects receive antimicrobial cover MRSA ( e.g . cotrimoxazole , rifampin , linezolid )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>outpatient</keyword>
	<keyword>skin soft tissue infection</keyword>
	<keyword>vancomycin intravenous</keyword>
</DOC>